Background: The Incidence of verified thrombotic events after elective spine surgery is 18%. Low-Molecular-Weight-Heparin (LMWH) is routinely given on the day before surgery. A postoperative start of the thrombotic prophylaxis could be an advantage in cases with opening of the spinal canal and for preventing epidural bleeding. Patient and methods: This active-controlled non-inferiority trial compared the effectiveness and safety of LMWH started pre-or postoperatively in patients undergoing spinal surgery. We analysed the incidence of clinically symptomatic venous thromboembolism. Results: A total number of 241 patients were followed over 14.6 patient-years. The incidence risk of fatal thromboembolisms was 0.011 (95%CI 0.0003 to 0.06) for the group with preoperative treatment and 0.01 (95% CI 0.0002 to 0.04) for the postoperatively treated group. The crude risk ratio was 1.65 (95%CI 0.10 to 26.03). There was no statistically significant difference in risk across groups (p=0.72). The Poisson regression model including follow-up time showed an incidence rate ratio of 0.67 (95% 0.04 to 10.74, p=0.779). There was no increased risk for complications (p=0.211). Conclusion: This study demonstrates that the postoperative start of LMWH in the prophylaxis of thrombotic events in patients undergoing spinal surgery does not affect safety or the incidence of complications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.